Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Comera Life Sciences Holdings, Inc.CMRA · Entity 94670 | Member of 10% owner group | December 29, 2023 | January 11, 2024 |
| Ernexa Therapeutics Inc.ERNA · Entity 8278 | 10% owner | December 02, 2022 | March 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Comera Life Sciences Holdings, Inc.
Report date December 29, 2023 · Filed January 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 12.0% Senior Secured Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2024-12-29 | IndirectBy Denny Family Partners II, LLC | Not disclosed |
Reported balance
After 2023-12-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-29 · Purchase · Acquired Not disclosed · Balance Not disclosed F1: Denny Family Partners II, LLC ("DFP") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which DFP acquired (i) $107,622 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 3,913,526 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F2: The reporting person disclaims beneficial ownership of the securities held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2028-12-29 | IndirectBy Denny Family Partners II, LLC | 3,913,526 |
Reported balance
After 2023-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-29 · Purchase · Acquired 3,913,526 · Balance 3,913,526 F1: Denny Family Partners II, LLC ("DFP") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which DFP acquired (i) $107,622 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 3,913,526 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F2: The reporting person disclaims beneficial ownership of the securities held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Denny Family Partners II, LLC ("DFP") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which DFP acquired (i) $107,622 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 3,913,526 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof.
F2: The reporting person disclaims beneficial ownership of the securities held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein.
Ernexa Therapeutics Inc.
Report date December 02, 2022 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Denny Family Partners II, LLC | 50,453 |
Reported balance
Holding disclosure · report date 2022-12-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 50,453 F1: The reporting person disclaims beneficial ownership of the shares held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy George P. Denny III Trust 6/11/81 | 406,785 |
Reported balance
Holding disclosure · report date 2022-12-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 406,785 |
| Common StockSEC Table I · non-derivative | Direct | 204 |
Reported balance
Holding disclosure · report date 2022-12-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 204 |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy George P. Denny III Trust 6/11/81 | Not disclosed |
Reported balance
Holding disclosure · report date 2022-12-02 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: The reporting person holds 71,306 shares of Series A preferred stock, which are currently convertible into 2971 shares of common stock. The reporting person has the right at any time to convert the shares of Series A preferred stock into that number of fully paid and nonassessable shares of common stock that equals the number of shares of Series A preferred stock that are surrendered for conversion divided by the conversion rate. The conversion rate was initially 100% and is subject to adjustment as provided in the Issuer's restated certificate of incorporation, as amended. The Series A preferred stock has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person disclaims beneficial ownership of the shares held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein.
F2: The reporting person holds 71,306 shares of Series A preferred stock, which are currently convertible into 2971 shares of common stock. The reporting person has the right at any time to convert the shares of Series A preferred stock into that number of fully paid and nonassessable shares of common stock that equals the number of shares of Series A preferred stock that are surrendered for conversion divided by the conversion rate. The conversion rate was initially 100% and is subject to adjustment as provided in the Issuer's restated certificate of incorporation, as amended. The Series A preferred stock has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2023 Filed Jan 11, 2024 19:14 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseWarrants to Purchase Common Stock · Derivative | 3,913,526 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001104659-24-003414 · tm243228-2_4seq1.xml · derivative · entry 2 DENNY GEORGE P III · CIK 0001234956 · Member of 10% owner group 10b5-1 filing: No plan indicated Ownership: Indirect · By Denny Family Partners II, LLC Disclosed balance after: 3,913,526 Underlying: Common Stock · 3,913,526 shares Expires 2028-12-29 F1 · kind: Denny Family Partners II, LLC ("DFP") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which DFP acquired (i) $107,622 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 3,913,526 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F1 · price: Denny Family Partners II, LLC ("DFP") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which DFP acquired (i) $107,622 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 3,913,526 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the securities held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| December 29, 2023 Filed Jan 11, 2024 19:14 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | Purchase12.0% Senior Secured Convertible Notes · Derivative | Not disclosed | $107,622.00 Strike: $0.06 | $107,622.00 |
DisclosureSEC source: 0001104659-24-003414 · tm243228-2_4seq1.xml · derivative · entry 1 DENNY GEORGE P III · CIK 0001234956 · Member of 10% owner group 10b5-1 filing: No plan indicated Ownership: Indirect · By Denny Family Partners II, LLC Disclosed balance after: Not disclosed Underlying: Common Stock · 1,956,763 shares Expires 2024-12-29 F1 · kind: Denny Family Partners II, LLC ("DFP") entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which DFP acquired (i) $107,622 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 3,913,526 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F2 · ownership.nature: The reporting person disclaims beneficial ownership of the securities held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein. Read SEC document |
| July 14, 2021 Filed Aug 20, 2021 17:38 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | PurchaseCommon Stock | 1 | $11.99 | $11.99 |
DisclosureSEC source: 0001062993-21-007818 · form4.xml · nonDerivative · entry 4 DENNY GEORGE P III · CIK 0001234956 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3 Read SEC document |
| July 09, 2021 Filed Aug 20, 2021 17:38 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | PurchaseCommon Stock | 1 | $14.11 | $14.11 |
DisclosureSEC source: 0001062993-21-007818 · form4.xml · nonDerivative · entry 3 DENNY GEORGE P III · CIK 0001234956 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2 Read SEC document |
| July 08, 2021 Filed Aug 20, 2021 17:38 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | PurchaseCommon Stock | 1 | $14.35 | $14.35 |
DisclosureSEC source: 0001062993-21-007818 · form4.xml · nonDerivative · entry 2 DENNY GEORGE P III · CIK 0001234956 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1 Read SEC document |
| July 06, 2021 Filed Aug 20, 2021 17:38 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | SaleCommon Stock | 75,000 | $16.06 | $1,204,687.50 |
DisclosureSEC source: 0001062993-21-007818 · form4.xml · nonDerivative · entry 1 DENNY GEORGE P III · CIK 0001234956 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Denny Family Partners II, LLC Disclosed balance after: 4,775,117 F1 · kind: The sale by Denny Family Partners II, LLC of BTX Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 3 shares, with the purchase of 3 shares of BTX Common Stock by the reporting person's spouse, also reported herein. The reporting person has agreed to pay to BTX, upon settlement of the sale, $8.78, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.41, inclusive. The reporting person undertakes to provide to Brooklyn ImmunoTherapeutics, Inc., any security holder of Brooklyn ImmunoTherapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2. F3 · ownership.nature: The reporting person disclaims beneficial ownership of the shares held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.